Study Finds That Bad Psychedelic Trips Double Some Individuals' Fatality Risk

Stock Information for ATAI Life Sciences N.V.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ATAI Life Sciences N.V.

atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
atai Life Sciences Announces Pricing of Public Offering of Common Shares
atai Life Sciences Announces Proposed Public Offering of Common Shares
atai Life Sciences Announces Positive Topline Results from Beckley Psytech's BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.